Many people with myasthenia gravis (MG) may see symptom changes during pregnancy—often worse in the first trimester or after birth—but most pregnancies end with a live baby and manageable complications.
Researchers looked at 34 studies with 3,720 pregnancies in people with MG and found that about 30% had worse MG symptoms during pregnancy, most often in the first trimester (the first three months).Around 27% had symptom flare-ups after giving birth (the postpartum period), so the weeks after delivery are a higher-risk time for symptoms to get worse.Different studies used different ways to measure “worse” symptoms, so numbers varied a lot. Think of it like using different thermometers—some give slightly different readings.About 9% of pregnancies ended in preterm birth (babies born before 37 weeks), and cesarean sections were done in about 32% of cases—higher than in the general population.Out of 1,530 babies reported, about 9% had newborn (neonatal) MG, which means the baby shows temporary muscle weakness after birth; this usually gets better with time and treatment.
People with MG and their caregivers should pay special attention in the first trimester and the weeks after birth, because those are the times symptoms are most likely to get worse—like stormy weather hitting at predictable times.Pregnant people with MG, and those planning pregnancy, should discuss birth plans with their healthcare team since cesarean or assisted delivery is more common, and planning helps avoid urgent surprises.New parents and neonatal teams should watch babies closely after birth for signs of newborn MG (weak feeding, weak cry, or breathing trouble) so treatment can start quickly if needed.Healthcare providers and midwives should be aware that MG can change during pregnancy and postpartum so they can adjust medications and support; think of it as tailoring a coat to fit changing weather.Caregivers who help with feeding, bathing, or moving the new parent should know that extra rest and help in the first trimester and after birth can be important because fatigue and muscle weakness may increase.
The studies included were different in quality and used different ways to measure symptom worsening, so the exact percentages (like 30% worse during pregnancy) are approximate rather than exact.Because most studies looked back at past cases instead of following people forward in time, we can’t be certain which factors (like specific medicines or other health issues) actually cause worse outcomes.More well-designed future studies are needed to clearly identify who is most at risk and which treatments are safest; until then, individualized care and close monitoring remain important.
AI-generated summary — for informational purposes only, not medical advice
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read More5/1/2026
Study found fewer hospital diagnoses of antibody-positive autoimmune encephalitis during COVID-19, b
Read More4/6/2026
Study finds NIK in myeloid cells boosts IL-23 and activates disease-driving T cells—pointing to a po
Read More3/17/2026
Study links Epstein-Barr virus protein to immune attacks on brain proteins in MS, explaining a possi
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.